Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period.

No definition available.

Name:	abbv_LossContingencyIndividualPlaintiffLawsuitsNumber
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws.

+ References

No definition available.

+ Details

Name:	abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of purported class actions filed, pertaining to a loss contingency during the period.

+ References

No definition available.

+ Details

Name:	abbv_LossContingencyPurportedClassActionsNumber
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Numbers of claims are consolidated for pre-trial purposes.

+ References

No definition available.

+ Details

Name:	abbv_NumberOfClaimsConsolidatedForPreTrialPurposes
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the percentage of pending claims in the United States District Courts.

+ References

No definition available.

+ Details

Name:	abbv_PercentageOfPendingClaimsInUnitedStatesDistrictCourts
Namespace Prefix:	abbv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents number of the number of individual punitive class action lawsuit.

+ References

No definition available.

+ Details

Name:	abbv_PunitiveClassActionLawsuitIndividualNumber
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of loss contingency liability.

+ References

+ Details

Name:	us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of damages awarded to the plaintiff in the legal matter.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349

+ Details

Name:	us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of plaintiffs that have filed claims pertaining to a loss contingency.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingencyNumberOfPlaintiffs
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of pending claims pertaining to a loss contingency.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

+ Details

Name:	us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=abbv_DepakoteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=abbv_AndroGelAntitrustLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=abbv_AllegationOfProposedGenericProductsInfringingPatentsAndSeekingDeclaratoryAndInjunctiveReliefMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=abbv_NiaspanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=abbv_TestosteroneReplacementTherapyProductsLiabilityLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=abbv_PunitiveDamagesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=abbv_CompensatoryDamagesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Legal Proceedings and Contingencies (Details)	1 Months Ended						3 Months Ended
Legal Proceedings and Contingencies (Details)	Mar. 31, 2018 USD ($) claim	Oct. 31, 2017 USD ($)	Jul. 31, 2017 USD ($)	Jun. 30, 2016 investment_fund	Nov. 30, 2014 individual	Sep. 30, 2014 company	Mar. 31, 2018 USD ($) direct_purchaser claim	Mar. 31, 2018 USD ($) company claim	Mar. 31, 2018 USD ($) claim	Mar. 31, 2018 USD ($) claim lawsuit	Mar. 31, 2018 USD ($) claim class_action	Mar. 31, 2018 USD ($) claim end_payor_purchaser	Dec. 31, 2017 USD ($)
Legal Proceedings and Contingencies
Recorded accrual balance for litigation \| $	$ 560,000,000						$ 560,000,000	$ 560,000,000	$ 560,000,000	$ 560,000,000	$ 560,000,000	$ 560,000,000	$ 445,000,000
Number of individual putative class action lawsuit				5	5
Depakote
Legal Proceedings and Contingencies
Number of claims pending \| claim	619						619	619	619	619	619	619
Percentage of pending claims in US District Courts									90.00%
AndroGel Antitrust Litigation
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into \| company								3
Number of individual plaintiff lawsuits \| lawsuit										4
Number of purported class actions \| class_action											3
AndroGel Antitrust Litigation \| Allegation of proposed generic products infringing AbbVie's patents and seeking declaratory and injunctive relief
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into \| company						2
Niaspan
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits \| lawsuit										4
Number of purported class actions \| class_action											2
Number of healthcare benefit providers who filed lawsuits							3					10
Testosterone Replacement Therapy Products Liability Litigation
Legal Proceedings and Contingencies
Numbers of claims are consolidated for pre-trial purposes \| claim	4,300						4,300	4,300	4,300	4,300	4,300	4,300
Number of claims pending \| claim	200						200	200	200	200	200	200
Testosterone Replacement Therapy Products Liability Litigation \| Punitive damages
Legal Proceedings and Contingencies
Damages awarded against company \| $	$ 3,000,000	$ 140,000,000	$ 150,000,000
Testosterone Replacement Therapy Products Liability Litigation \| Compensatory damages
Legal Proceedings and Contingencies
Damages awarded against company \| $	$ 200,000	$ 140,000	$ 0